Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Keren Osman, MD, Ajai Chari, Samir Parekh, MD, Adolfo Aleman, Jessica Caro, MD, Gillian Morgan, RN, Erika Florendo, NP, Elaine Chan, Gina Strumolo, Katarzyna Zarychta, Lisa La, BS, MS, John Mandeli, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Sundar Jagannath, MD, Hearn Jay Cho, MD PhD

Blood (2017) 130 (Supplement 1): 3282.

https://doi.org/10.1182/blood.V130.Suppl_1.3282.3282

Published: 2017

Journal Articles

Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Keren Osman, MD, Ajai Chari, MD, Samir Parekh, MD, Christine Pun, BS, Gillian Morgan, RN, Erika Florendo, ANP-BC, Elaine Chan, BS, Marisa Shields, Gina Strumolo, MA, Lisa La, MS/CCRP, John Mandeli, PhD, James Geerlof, BS, PA, Sundar Jagannath, MD, Hearn Jay Cho, MD PhD

Blood (2016) 128 (22): 3448.

https://doi.org/10.1182/blood.V128.22.3448.3448

Published: 2016

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, MD, Celia Grosskreutz, MD, Steven Fruchtman, MD, Janice Gabrilove, MD, John Mandeli, PhD, Luis Isola, MD

Blood (2005) 106 (11): 5315.

https://doi.org/10.1182/blood.V106.11.5315.5315

Published: 2005

Journal Articles

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Janice L. Gabrilove, MD, Melanie-Jane McConnell, MD, Windy Berkofsky-Fessler, MD, Andres L. Sirulnik, MD, PhD, Sanjay Sharma, MD, Lewis R. Silverman, MD, Luis Isola, MD, John Mandeli, PhD, Jonathan Licht, MD

Blood (2005) 106 (11): 2799.

https://doi.org/10.1182/blood.V106.11.2799.2799

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only